Providing a lifeline to medical providers and patients alike, the Drug Enforcement Administration (“DEA”) along with the Department of Health and Human Services (“HHS”) made a crucial move, announcing the prolongation of the COVID-19 telemedicine flexibilities for the prescription of controlled medications, known as the “Second Temporary Rule”. Filed on Friday, October 6, 2023, this extension, allows the continuation of telemedicine flexibilities initially implemented during the COVID-19 public health emergency (“PHE”) and now lasts until the end of 2024 – December 31 in specific.
The encapsulated provisions originated as an emergency measure for the COVID-19 period, providing a significant flexibility for medical providers to prescribe necessary controlled substances remotely, bridging the physical gap caused by the need for social distancing.
The DEA and HHS’s move to extend these flexibilities further recognizes the value and effectiveness of telemedicine, as well as demonstrating the agencies’ commitment to improving patient access to critical medications in times of widespread public health concerns.
For legal professionals involved in the healthcare sector, it is important to note that the Second Temporary Rule is scheduled for publication in the Federal Register. This will likely hold significant implications for telemedicine operations and prescribing practices across the country.
In-depth details about the impact of this extension can be found on
JDSupra.